Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Dianthus Therapeutics, Inc. /DE/

Get SEC filing alerts via email and in your feed for Dianthus Therapeutics, Inc. /DE/

DNTH

Dianthus Therapeutics, Inc. /DE/

About Dianthus Therapeutics, Inc. /DE/

Dianthus Therapeutics is a biotech company developing targeted complement system therapeutics for autoimmune and inflammatory diseases. Its lead candidate, DNTH103, is a monoclonal antibody designed to selectively inhibit active C1s, aiming for improved safety, efficacy, and convenience. The company focuses on diseases like myasthenia gravis, CIDP, and MMN, leveraging proprietary technology and strategic licensing to advance innovative, patient-friendly biologics.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Dianthus Therapeutics, Inc. /DE/

1
1
Dianthus Therapeutics, Inc. /DE/ Dianthus Therapeutics Reports $40.8 Million Net Loss and $463,000 Revenue in Q1 2026

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Dianthus Therapeutics, Inc. /DE/ Dianthus Therapeutics Reports 2025 Financial Results and Operational Updates

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Dianthus Therapeutics, Inc. /DE/ Dianthus Therapeutics Reports Q3 2025 Revenue Decline and Increased Net Loss

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Dianthus Therapeutics, Inc. /DE/ Dianthus Therapeutics Reports $31.6 Million Net Loss in Q2 2025, Revenue Declines to $193,000

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Dianthus Therapeutics, Inc. /DE/ Dianthus Therapeutics Reports $1.2 Million Revenue in Q1 2025, Net Loss of $29.5 Million

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Dianthus Therapeutics, Inc. /DE/ Dianthus Therapeutics Reports $84.97 Million Net Loss and $6.24 Million Revenue for 2024

Via official filing (AI summary) | about 1 year ago | 0 comments